Shuang Liu1, Xiaoliang Wang1, Yuanshan Lu2, Tao Li1, Zijun Gong1, Tao Sheng1, Bin Hu3, Zhihai Peng4, Xing Sun5. 1. Department of General Surgery, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, 100 Haining Road, Shanghai, 200080, China. 2. Department of Transfusion, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 3. Department of Gastroenterology, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 4. Department of General Surgery, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, 100 Haining Road, Shanghai, 200080, China. zhihai.peng@hotmail.com. 5. Department of General Surgery, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, 100 Haining Road, Shanghai, 200080, China. xingsun@hotmail.com.
Abstract
PURPOSE: The definition of risk factors associated with acute renal failure (ARF) following orthotropic liver transplantation (OLT) is still controversial. Cryoprecipitate, which can supply fibrinogen and other coagulation factors, is widely used in OLT. However, the effects of intraoperative cryoprecipitate transfusion on ARF following OLT remain unclear. METHODS: In a series of 389 adult patients who received grafts from deceased donors and underwent their first OLT, the clinical correlation between intraoperative cryoprecipitate transfusion and ARF following OLT was retrospectively studied after adjusting for potential confounders. The distribution of ARF and the causes of death within the first year after OLT were also compared separately in patients with and without cryoprecipitate transfusion. RESULTS: The incidence of ARF in patients with cryoprecipitate transfusion was significantly higher than in patients without cryoprecipitate transfusion (15.9 vs. 7.8 %, p = 0.012). A nonlinear relationship between intraoperative cryoprecipitate transfusion and ARF following OLT was observed. The risk of ARF increased with the cryoprecipitate transfusion level up to the turning point (16 U) (adjusted OR 1.1, 95 % CI 1.1-1.2; p < 0.001). When the cryoprecipitate level exceeded 16 U, the level of cryoprecipitate transfusion was not associated with the risk of ARF (OR 0.95, 95 % CI 0.85-1.1; p = 0.319). Deaths within the first year after the operation occurred more frequently in cases with cryoprecipitate transfusion (22.9 vs. 14.2 %, p = 0.029). CONCLUSIONS: These findings suggested that intraoperative cryoprecipitate transfusion is associated with ARF following OLT. Cryoprecipitate transfusion during OLT should be performed carefully until more convincing evidence has been found.
PURPOSE: The definition of risk factors associated with acute renal failure (ARF) following orthotropic liver transplantation (OLT) is still controversial. Cryoprecipitate, which can supply fibrinogen and other coagulation factors, is widely used in OLT. However, the effects of intraoperative cryoprecipitate transfusion on ARF following OLT remain unclear. METHODS: In a series of 389 adult patients who received grafts from deceased donors and underwent their first OLT, the clinical correlation between intraoperative cryoprecipitate transfusion and ARF following OLT was retrospectively studied after adjusting for potential confounders. The distribution of ARF and the causes of death within the first year after OLT were also compared separately in patients with and without cryoprecipitate transfusion. RESULTS: The incidence of ARF in patients with cryoprecipitate transfusion was significantly higher than in patients without cryoprecipitate transfusion (15.9 vs. 7.8 %, p = 0.012). A nonlinear relationship between intraoperative cryoprecipitate transfusion and ARF following OLT was observed. The risk of ARF increased with the cryoprecipitate transfusion level up to the turning point (16 U) (adjusted OR 1.1, 95 % CI 1.1-1.2; p < 0.001). When the cryoprecipitate level exceeded 16 U, the level of cryoprecipitate transfusion was not associated with the risk of ARF (OR 0.95, 95 % CI 0.85-1.1; p = 0.319). Deaths within the first year after the operation occurred more frequently in cases with cryoprecipitate transfusion (22.9 vs. 14.2 %, p = 0.029). CONCLUSIONS: These findings suggested that intraoperative cryoprecipitate transfusion is associated with ARF following OLT. Cryoprecipitate transfusion during OLT should be performed carefully until more convincing evidence has been found.
Authors: Giuseppe Fusai; Parveen Dhaliwal; Nancy Rolando; Caroline Anne Sabin; David Patch; Brian Ritchie Davidson; Andrew Kenneth Burroughs; Keith Rolles Journal: Liver Transpl Date: 2006-11 Impact factor: 5.799
Authors: Daniel L Sprague; Bennett D Elzey; Scott A Crist; Thomas J Waldschmidt; Robert J Jensen; Timothy L Ratliff Journal: Blood Date: 2008-01-15 Impact factor: 22.113
Authors: R Rull; J C García-Valdecasas; L Grande; J Tabet; J Fuster; A M Lacy; A Rimola; F X Gonzalez; C Ramos; J Visa Journal: Transplant Proc Date: 1997 Feb-Mar Impact factor: 1.066
Authors: Jie Chen; Terry Singhapricha; Ke-Qin Hu; Johnny C Hong; Randolph H Steadman; Ronald W Busuttil; Victor W Xia Journal: Transplantation Date: 2011-02-15 Impact factor: 4.939
Authors: Yousri M Barri; Edmund Q Sanchez; Linda W Jennings; Larry B Melton; Steven Hays; Marlon F Levy; Goran B Klintmalm Journal: Liver Transpl Date: 2009-05 Impact factor: 5.799
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097